Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
ALX Oncology Holdings Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
ALXO
Nasdaq
2836
www.alxoncology.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for ALX Oncology Holdings Inc.
Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year?
- May 12th, 2026 7:40 am
ALX Oncology Holdings Inc. Q1 2026 Earnings Call Summary
- May 9th, 2026 6:30 am
ALX Oncology Q1 Earnings Call Highlights
- May 8th, 2026 8:57 am
ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update
- May 8th, 2026 6:00 am
ALX Oncology’s Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression
- May 7th, 2026 6:00 am
Favourable Signals For ALX Oncology Holdings: Numerous Insiders Acquired Stock
- May 2nd, 2026 6:32 am
ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026
- Apr 30th, 2026 6:00 am
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
- Apr 17th, 2026 2:05 pm
bioAffinity Stock Surges 113.8% in 3 Months: What's Driving the Rally?
- Apr 16th, 2026 7:55 am
ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer
- Apr 13th, 2026 6:30 am
ALDX Crashes 71% as FDA Issues Third CRL for Dry Eye Disease Drug NDA
- Mar 18th, 2026 9:10 am
CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data
- Mar 17th, 2026 8:40 am
IBRX Stock Jumps on Progress in NK Cell Therapy Production
- Mar 16th, 2026 11:35 am
JNJ's Bladder Cancer Therapy Meets Key Goal in Early-Stage Study
- Mar 16th, 2026 10:59 am
Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q4
- Mar 13th, 2026 9:24 am
ALX Oncology initiated with a Buy at UBS
- Mar 7th, 2026 6:25 am
LRMR Stock on the Move: What Sparked the 55% Jump in the Past Month?
- Mar 6th, 2026 8:26 am
Mirum Completes Enrollment & Screening in Liver Disease Studies
- Mar 6th, 2026 6:27 am
ALX Oncology Highlights $150M Raise, Evorpacept Breast Cancer Push and EGFR ADC ALX2004 Update
- Mar 3rd, 2026 9:34 pm
ALX Oncology Holdings Inc (ALXO) Q4 2025 Earnings Call Highlights: Strong Clinical Progress and ...
- Feb 27th, 2026 2:04 pm
Scroll